The impact of amyloid-beta positivity with 18f-florbetaben pet on neuropsychological aspects in parkinson’s disease dementia

Seunghee Na; Hyeonseok Jeong; Jong Sik Park; Yong An Chung; In Uk Song

doi:10.3390/metabo10100380

The impact of amyloid-beta positivity with 18f-florbetaben pet on neuropsychological aspects in parkinson’s disease dementia

Seunghee Na
, Hyeonseok Jeong
, Jong Sik Park
, Yong An Chung
, In Uk Song

The Catholic University of Korea Incheon St. Mary's Hospital

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The neuropathology of Parkinson’s disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. The aim of this study was to evaluate the frequency and impacts of co-existence with Alzheimer’s disease in patients with PDD by using 18F-florbetaben PET imaging. A total of 23 patients with PDD participated in the study. All participants underwent 18F-florbetaben PET and completed a standardized neuropsychological battery and assessment of motor symptoms. The results of cognitive tests, neuropsychiatric symptoms, and motor symptoms were analyzed between the positive and negative 18F-florbetaben PET groups. Four patients (17.4%) showed significant amyloid burden. Patients with amyloid-beta showed poorer performance in executive function and more severe neuropsychiatric symptoms than those without amyloid-beta. Motor symptoms assessed by UPDRS part III and the modified H&Y Scale were not different between the two groups. The amyloid PET scan of a patient with PDD can effectively reflect a co-existing Alzheimer’s disease pathology. Amyloid PET scans might be able to help physicians of PDD patients showing rapid progression or severe cognitive/behavioral features.

Original language	English
Article number	380
Pages (from-to)	1-7
Number of pages	7
Journal	Metabolites
Volume	10
Issue number	10
DOIs	https://doi.org/10.3390/metabo10100380
State	Published - Oct 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alzheimer’s disease
Executive function
Neuropsychiatric symptoms
Parkinson’s disease dementia
Positron emission tomography

Access to Document

10.3390/metabo10100380

Cite this

@article{2ade47b5f99d42a394bad2093fa0cb5f,

title = "The impact of amyloid-beta positivity with 18f-florbetaben pet on neuropsychological aspects in parkinson{\textquoteright}s disease dementia",

abstract = "The neuropathology of Parkinson{\textquoteright}s disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. The aim of this study was to evaluate the frequency and impacts of co-existence with Alzheimer{\textquoteright}s disease in patients with PDD by using 18F-florbetaben PET imaging. A total of 23 patients with PDD participated in the study. All participants underwent 18F-florbetaben PET and completed a standardized neuropsychological battery and assessment of motor symptoms. The results of cognitive tests, neuropsychiatric symptoms, and motor symptoms were analyzed between the positive and negative 18F-florbetaben PET groups. Four patients (17.4\%) showed significant amyloid burden. Patients with amyloid-beta showed poorer performance in executive function and more severe neuropsychiatric symptoms than those without amyloid-beta. Motor symptoms assessed by UPDRS part III and the modified H\&Y Scale were not different between the two groups. The amyloid PET scan of a patient with PDD can effectively reflect a co-existing Alzheimer{\textquoteright}s disease pathology. Amyloid PET scans might be able to help physicians of PDD patients showing rapid progression or severe cognitive/behavioral features.",

keywords = "Alzheimer{\textquoteright}s disease, Executive function, Neuropsychiatric symptoms, Parkinson{\textquoteright}s disease dementia, Positron emission tomography",

author = "Seunghee Na and Hyeonseok Jeong and Park, \{Jong Sik\} and Chung, \{Yong An\} and Song, \{In Uk\}",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = oct,

doi = "10.3390/metabo10100380",

language = "English",

volume = "10",

pages = "1--7",

journal = "Metabolites",

issn = "2218-1989",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - The impact of amyloid-beta positivity with 18f-florbetaben pet on neuropsychological aspects in parkinson’s disease dementia

AU - Na, Seunghee

AU - Jeong, Hyeonseok

AU - Park, Jong Sik

AU - Chung, Yong An

AU - Song, In Uk

PY - 2020/10

Y1 - 2020/10

N2 - The neuropathology of Parkinson’s disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. The aim of this study was to evaluate the frequency and impacts of co-existence with Alzheimer’s disease in patients with PDD by using 18F-florbetaben PET imaging. A total of 23 patients with PDD participated in the study. All participants underwent 18F-florbetaben PET and completed a standardized neuropsychological battery and assessment of motor symptoms. The results of cognitive tests, neuropsychiatric symptoms, and motor symptoms were analyzed between the positive and negative 18F-florbetaben PET groups. Four patients (17.4%) showed significant amyloid burden. Patients with amyloid-beta showed poorer performance in executive function and more severe neuropsychiatric symptoms than those without amyloid-beta. Motor symptoms assessed by UPDRS part III and the modified H&Y Scale were not different between the two groups. The amyloid PET scan of a patient with PDD can effectively reflect a co-existing Alzheimer’s disease pathology. Amyloid PET scans might be able to help physicians of PDD patients showing rapid progression or severe cognitive/behavioral features.

AB - The neuropathology of Parkinson’s disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. The aim of this study was to evaluate the frequency and impacts of co-existence with Alzheimer’s disease in patients with PDD by using 18F-florbetaben PET imaging. A total of 23 patients with PDD participated in the study. All participants underwent 18F-florbetaben PET and completed a standardized neuropsychological battery and assessment of motor symptoms. The results of cognitive tests, neuropsychiatric symptoms, and motor symptoms were analyzed between the positive and negative 18F-florbetaben PET groups. Four patients (17.4%) showed significant amyloid burden. Patients with amyloid-beta showed poorer performance in executive function and more severe neuropsychiatric symptoms than those without amyloid-beta. Motor symptoms assessed by UPDRS part III and the modified H&Y Scale were not different between the two groups. The amyloid PET scan of a patient with PDD can effectively reflect a co-existing Alzheimer’s disease pathology. Amyloid PET scans might be able to help physicians of PDD patients showing rapid progression or severe cognitive/behavioral features.

KW - Alzheimer’s disease

KW - Executive function

KW - Neuropsychiatric symptoms

KW - Parkinson’s disease dementia

KW - Positron emission tomography

UR - https://www.scopus.com/pages/publications/85091660857

U2 - 10.3390/metabo10100380

DO - 10.3390/metabo10100380

M3 - Article

AN - SCOPUS:85091660857

SN - 2218-1989

VL - 10

SP - 1

EP - 7

JO - Metabolites

JF - Metabolites

IS - 10

M1 - 380

ER -

The impact of amyloid-beta positivity with 18f-florbetaben pet on neuropsychological aspects in parkinson’s disease dementia

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this